Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
SMP-656 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 August 2026
SMP-656: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SGB-3908 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 August 2026
SGB-3908: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
GSK-3326595 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 August 2026
GSK-3326595: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ALG-055009 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 August 2026
ALG-055009: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
OpRegen (Lineage Cell Therapeutics) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 August 2026
OpRegen (Lineage Cell Therapeutics): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Varoglutamstat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 August 2026
Varoglutamstat: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Tecarfarin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 August 2026
Tecarfarin: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Mizagliflozin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 August 2026
Mizagliflozin: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
CHRNA10 Biologics Sequence Review Report 2026: Neuronal acetylcholine receptor subunit alpha-10 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CHRNA10 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CHRNA3 Biologics Sequence Review Report 2026: Neuronal acetylcholine receptor subunit alpha-3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CHRNA3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CHRNA2 Biologics Sequence Review Report 2026: Neuronal acetylcholine receptor subunit alpha-2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CHRNA2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CHRNA1 Biologics Sequence Review Report 2026: Acetylcholine receptor subunit alpha Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CHRNA1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.